57 results about "Drug availability" patented technology

A care system and associated methods are provided for alleviating patient pain, anxiety and discomfort associated with medical or surgical procedures. The system comprises: at least one patient health monitor device coupled to a patient and generating a signal reflecting at least one physiological condition of the patient; a drug delivery controller supplying one or more drugs to the patient; a memory device storing a safety data set reflecting parameters of at least one patient physiological condition; and an electronic controller interconnected between the patient health monitor, the drug delivery controller and the safety data set. The electronic controller is capable of effecting a change in the drug supply delivered to the patient and the generation of current signals by the patient health monitor device depending on a comparison between at least one patient physiological condition at its corresponding value reflected in the safety data set.

Highly concentrated drug particle formulations are described, wherein the drug comprises between about 25 wt % and 80 wt % of the particle formulation. The particle formulations of the present invention comprise, for example, macromolecules, such as proteins and/or small molecules (such as steroid hormones). The particle formulation typically further includes one or more additional component, for example, one or more stabilizer (e.g., carbohydrates, antioxidants, amino acids, and buffers). Such concentrated particle formulations can be combined with a suspension vehicle to form suspension formulations. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a highly concentrated drug particle formulation. Devices for delivering the suspension formulations and methods of use are also described. The present invention provides needed improvements in drug formulation and delivery to improve patient compliance and expand drug availability.

The invention is directed to compositions comprising at least one nanoparticulate H1-histamine receptor antagonist, such as ebastine or a salt or derivative thereof, having improved dissolution rate providing a faster onset of drug availability. The nanoparticulate H1-histamine receptor antagonist particles, such as ebastine, have an effective average particle size of less than about 2000 nm and are useful in the treatment of seasonal and perennial allergic rhinitis and related diseases.

A medication injector that has an alert indicator that alerts the user when the medication injector is approaching near the end of its medication supply is disclosed. The alert indicator gives the user an opportunity to make preparations to obtain additional medication for the injector if there is an insufficient amount of medication in the injector to enable the user to dispense the required dosage amount with the next injection. Initially, the alert indicator is not visible to the user, but becomes visible to the user when the injector is near empty.

A method of manufacture of ECM microparticles incorporating bioactive molecules for drug delivery has been developed, using a modified emulsification method or a water-in-oil-phase-separation method. The microspheres are photochemically crosslinked to control the release of the bioactive molecules for better drug delivery usage without compromising the biocompatibility of the crosslinked structures. The method uses mild fabrication conditions and simple processes, no toxic chemical crosslinking reagent, which may cause cytotoxicity and calcification after implantation, no organic solvents, which may reduce drug availability and bioactivity, and no vigorous stirring action, which may fragmentize material with poor shape and mechanical stability and thus destabilize the emulsion. The resulting microparticles or microspheres are of controlled size, controlled release, highly biocompatible, and useful for drug delivery as well as cell culture.

The invention relates to a captopril-carrying nano-grade fiber sustained-release system and a preparation method thereof. The sustained-release system comprises the components of: a biodegradable high-molecular material and captopril. The drug-loading rate of the system is 8-80wt%, and the diameter of the nano-grade fiber is 80nm-1.20mum. The preparation method comprises the steps that: (1) the biodegradable high-molecular material is dissolved in an organic solvent; the mixture is stirred until the material is completely dissolved; captopril is added and the mixture is stirred; the mixture is subjected to ultrasonic deaeration, such that a spinning liquid is obtained; (2) the spinning liquid is added into an injector, and electrostatic spinning is carried out, such that the captopril-carrying nano-grade fiber sustained-release system is obtained. According to the invention, with the nano-grade sustained-release system composed of the drug-carrying nano-grade fiber, drug release is effectively controlled. The biodegradable high-molecular material can be automatically degraded with human metabolism, such that an effect of sustained-release is achieved. The process is simple, an equipment cost is low, the conditions are easy to control, and drug availability is improved.

A method of manufacture of ECM microparticles incorporating bioactive molecules for drug delivery has been developed, using a modified emulsification method or a water-in-oil-phase-separation method. The microspheres are photochemically crosslinked to control the release of the bioactive molecules for better drug delivery usage without compromising the biocompatibility of the crosslinked structures. The method uses mild fabrication conditions and simple processes, no toxic chemical crosslinking reagent, which may cause cytotoxicity and calcification after implantation, no organic solvents, which may reduce drug availability and bioactivity, and no vigorous stirring action, which may fragmentize material with poor shape and mechanical stability and thus destabilize the emulsion. The resulting microparticles or microspheres are of controlled size, controlled release, highly biocompatible, and useful for drug delivery as well as cell culture.

The invention relates to an ofloxacin molecular inclusion nanometer preparation and a preparation method thereof, belonging to the technical field of medicines. The main raw materials of the molecular inclusion nanometer preparation are cyclodextrin, solubilizer, polymer materials, ofloxacin and the like. The preparation method comprises the steps of: adding the cyclodextrin after dissolving the ofloxacin in a solution containing the solubilizer and preparing a molecular inclusion compound through a gradient ultrasonic grinding method; then adding the polymer materials for grinding; and drying and smashing to obtain the ofloxacin molecular inclusion nanometer preparation. The average particle size of the molecular inclusion nanometer preparation is 252.3 nm; and the drug content is 1%-25%. The preparation method, disclosed by the invention, has the advantages of being simple in a preparation process, high in drug carrying amount and stability, controllable in quality, suitable for industrial production and the like. The ofloxacin molecular inclusion nanometer preparation prepared by the method has the advantages of efficiently improving stability of the drug and dissolution degree as well as dissolution speed of the drug in a gastrointestinal tract, improving a drug absorption rate, realizing rapid and efficient effects, masking bitter taste of the drug, reducing drug irradiation and improving drug palatability and drug availability.

The invention relates to an intestine and stomach administration bioadhesive microsphere preparation and a preparation method of the intestine and stomach administration bioadhesive microsphere preparation, and belongs to the technical field of medical preparations. A natural polymeric amylose compound is prepared from lactose and pectin to serve as a drug-loaded material, and is quite excellent in biocompatibility, high in drug loading capacity, good in spheronization and slow release feature; and the side effect of a drug reaches the lowest level. Soybean lecithin is used to improve the lipid solubility of the drug and strengthens the membrane permeability, the retention time on an absorption part in vivo is prolonged, the drug release and the membrane permeation absorption are promoted,the drug availability is improved, meanwhile, the soybean lecithin and hydrophobin produces a synergistic effect, the hydrophobin molecule is folded, a hydrophobic group and a sulfydryl embedded in the hydrophobin are exposed, so that the hydrophobic interaction of the hydrophobin is strengthened, the hydrophobic effect and the mutual electrostatic interaction between an amino acid residue on thehydrophobin and a mucosa protein are strengthened, the disulfide bond formed by a cysteine residue on the hydrophobin and a thiol group of a glycoprotein in a mucus is increased, and the bioadhesiveperformance is strengthened.

The invention relates to a traditional Chinese medicine composition, and particularly relates to a capsule for treating ulcerative colitis. The content of the capsule is composed of the following ingredients in parts by weight: 24-56 parts of Radix Aucklandiae instant micropills and 49-105 parts of Rhizoma Coptidis colon-targeted micropills, wherein the Radix Aucklandiae instant micropills are composed of the following ingredients in parts by weight: 1 part of a Radix Aucklandiae volatile oil, 8-15 parts of beta-CD (cyclodextrin) and 16-40 parts of a shaping agent; and the Rhizoma Coptidis colon-targeted micropills are composed of the following ingredients in parts by weight: 24 parts of a Rhizoma Coptidis extract, 24-72 parts of a pill core excipient, 0.36-1.2 parts of acrylic resin L100-55, 1.08-3.6 parts of acrylic resin S100, 0.043-0.144 parts of diethyl phthalate and 0.28-0.96 parts of talcum powder. The capsule provided by the invention can separately release two different functional ingredients in the stomach and colon, and has the advantage of high drug availability.

The invention provides a polypeptide drug conjugate as well as a preparation method and application thereof. The polypeptide drug conjugate is prepared from ticagrelor and CREKA polypeptide, wherein the ticagrelor is connected with the CREKA polypeptide. Compared with the existing platelet inhibitor, the polypeptide drug conjugate provided by the invention not only can achieve high concentration enrichment of tumor tissue sites, but also realizes high concentration enrichment in atherosclerosis tissues by connecting the ticagrelor with the polypeptide, so that the platelet function in specificareas is inhibited without affecting platelet function during normal blood circulation, the bleeding risk of the conventional platelet inhibitor is reduced while the drug availability is improved, and better and safer tumor metastasis inhibition or acute coronary syndrome prevention function is accordingly realized.

The invention relates to the technical field of conveying equipment, and discloses a medicine supply chain conveying device and method.The medicine supply chain conveying device comprises a shell, conveying wheels are rotationally installed on the inner side and the outer side of the shell correspondingly, the two conveying wheels are in transmission connection with the same conveying belt, and a sweeping wheel is rotationally installed at the bottom of the inner side of the shell; a swing rod is rotatably mounted at the top of the inner side of the shell, a spray head is fixedly mounted at the bottom end of the swing rod, one end of a spring is fixedly mounted on one side of the swing rod, the other end of the spring is fixedly mounted on the inner wall of the top of the shell, a fixed pulley is rotatably mounted on one side of the top of the shell, and a traction rope movably abuts against the outer side of the fixed pulley. The medicine conveying and drying device is reasonable in design, medicine conveying and drying work can be synchronously carried out, so that the medicine production efficiency is improved, the time saving effect is achieved, the cleaning work of the conveying belt can be completed through the arrangement of the cleaning wheels, and the medicine quality is guaranteed.

The invention relates to the field of medicines and in particular relates to a traditional Chinese medicine composition with effects of beautifying and protecting skin as well as a preparation methodand application thereof. The traditional Chinese medicine composition is prepared from the following medicines in parts by weight: 15-25 parts of black false hellebore, 15-25 parts of sweet wormwood,15-25 parts of wheat straws, 15-25 parts of buckwheat straws, 15-25 parts of eggplant stalks, 20-30 parts of wax gourd vines, 20-30 parts of mulberry, 20-30 parts of herba portulacae, 30-50 parts of halite, 30-50 parts of lime and 40-50 parts of folium artemisiae argyi. The traditional Chinese medicine composition disclosed by the invention is prepared by a scientific method by virtue of reasonable compatibility, so that the product is stable in drug efficacy, rapid in efficacy, convenient to use, fast in effects and obvious in curative effects, has the effects of removing necrotic tissue andevil, eliminating melanin, healing sore and promoting granulation, beautifying and protecting skin and the like, has excellent effects in the aspect of removing melanoma, age pigment, common wart, plane warts and yellow-face warts, and does not have any toxic or side effect. Moreover, due to the mutual effects of the active ingredients, the drug availability is high, and the best synergistic treatment effect can be achieved.

The invention relates to a traditional Chinese medicine composition for treating infantile ascariasis and a preparation method thereof. The traditional Chinese medicine composition is characterized by being prepared from, by weight, 11-13 parts of coix seeds, 11-13 parts of stone-like omphalia, 8-10 parts of Chinese waxgourd seeds, 8-10 parts of poria cocos, 8-10 parts of talc, 5-7 parts of apricot kernels, 5-7 parts of rhizoma pinelliae, 5-7 parts of fructus amomi, 5-7 parts of dried ginger, 5-7 parts of peppers, 5-7 parts of dried tangerine peel, 5-7 parts of fructus hordei germinatus, 5-7 parts of hawthorn fruit, 5-7 parts of medicated leaven, 5-7 parts of nutgrass galingale rhizomes, 5-7 parts of cyrtomium rhizomes, 5-7 parts of green tangerine peel, 5-7 parts of szechwan chinaberry fruit and 2-4 parts of rheum officinale. The traditional Chinese medicine composition has the advantages of being good in curative effect, quick in efficacy, free of side effect, advanced in preparation technology, good in preparation stability, high in drug availability and the like; it is clinically proved that the effective rate of the traditional Chinese medicine composition for treating the infantile ascariasis is 100%.